#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Clinical Osteology / 2019 - 1

Effect of long-term treatment with growth hormone on bone density and bone quality

Czech version

Authors: Kužma Martin;  Stojkovičová Dáša;  Payer Juraj
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in: Clinical Osteology 2019; 24(1): 23-26
Category:

Overview

Growth hormone (GH) affects bone metabolism directly by binding to GH receptor or indirectly by IGF-1. The anabolic effect of GH is essential for peak bone mass (PBM) and appropriate trabecular bone microarchitecture during adolescence and early adulthood. In short-term studies, the effect of GH replacement on bone mineral density (BMD) in adults with GH deficiency (GHD) was not observed. BMD increases are only observed in studies longer than 12–24 months. A gradual rise in BMD was then observed even after 5–7 years of GH treatment. At present, it is believed that impaired bone strength and microstructure is more important in fracture development than BMD. Although short-term studies have confirmed the positive effect of RH treatment on bone quality parameters, long-term data are insufficient.

Keywords:

bone mineral density – Growth hormone – peak bone mass

Sources
  1. Harrison TR, Kasper DL, Fauci AS et al. Harrison‘s Principles of Internal Medicine 19th ed. McGraw-Hill Education: 2015. ISBN 978–0071802154.
  2. Lindsey RC, Mohan S. Skeletal effects of growth hormone and insulin-like growth factor-I therapy. Mol Cell Endocrinol 2016; 432: 44–55. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mce.2015.09.017>.
  3. Monson JP, Brooke AM, Akker S. Adult Growth Hormone Deficiency. In: Feingold KR, Anawalt B, Boyce A et al (eds). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.: 2000–2015.
  4. Kuzma M, Jackuliak P, Killinger Z et al. Problematika sekundárnej osteoporózy pri deficite rastového hormónu v dospelosti. [Issues related to secondary osteoporosis associated with growth hormone deficiency in adulthood]. Vnitr Lek 2017; 63(10): 658–661.
  5. Boguszewski CL. Update on GH therapy in adults. F1000Research 2017; 6: 2017. Dostupné z DOI: <http://dx.doi.org/10.12688/f1000research.12057.1>.
  6. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016; 19(1): 82–92. Dostupné z DOI: <http://dx.doi.org/10.1007/s11102–015–0671–4>.
  7. Hans D, Goertzen AL, Krieg MA et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 2011; 26(11): 2762–2769. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.499>.
  8. Kuzma M, Binkley N, Bednarova A et al. Trabecular Bone Score Change Differs with Regard to 25(Oh)D Levels in Patients Treated for Adult-Onset Growth Hormone Deficiency. Endocr Pract 2016; 22(8): 951–958. Dostupné z DOI: <http://dx.doi.org/10.4158/EP151183.OR>.
  9. Appelman-Dijkstra NM, Claessen KM, Hamdy NA et al. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf) 2014;81(5): 727–735. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12493>.
  10. Kuzma M, Kuzmova Z, Zelinkova Z et al. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res 2014; 24(1): 22–28. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ghir.2013.12.001>.
  11. Locatelli V, Bianchi VE. Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis. Int J Endocrinol 2014; 2014: 235060. Dostupné z DOI: <http://dx.doi.org/10.1155/2014/235060>.
  12. Kristensen E, Hallgrimsson B, Morck DW, Boyd SK. Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency. Int J Endocrinol 2012; 2012: 294965. Dostupné z DOI: Dostupné z DOI: <http://dx.doi.org/10.1155/2012/294965>.
  13. Saggese G, Baroncelli GI, Bertelloni S et al. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab 1996; 81(8): 3077–3083. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem.81.8.8768878>.
  14. Clanget C, Seck T, Hinke V, Wuster C, Ziegler R, Pfeilschifter J. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf) 2001; 55(1): 93–99.
  15. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 2012; 166(5): 787–795. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-11–1072>.
  16. Elbornsson M, Gotherstrom G, Franco C et al. Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency. Eur J Endocrinol 2012; 166(2): 181–189. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-11–0886>.
  17. Gotherstrom G, Bengtsson BA, Bosaeus I et al. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 2007; 156(1): 55–64. Dostupné z DOI: <http://dx.doi.org/10.1530/eje.1.02317>.
  18. Hyldstrup L, Conway GS, Racz K et al. Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency. Osteoporos Int 2012; 23(8): 2219–2226. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–011–1854–0>.
  19. Allo Miguel G, Serraclara Pla A, Partida Munoz ML, Martinez Diaz-Guerra G, Hawkins F. Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center. Ther Adv Endocrinol Metab 2016; 7(3): 93–100. Dostupné z DOI: <http://dx.doi.org/10.1177/2042018816643908>.
  20. McCloskey EV, Oden A, Harvey NC, Leslie WD, Hans D, Johansson H, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res 2016; 31(5): 940–948. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2734>.
  21. Bredella MA, Lin E, Gerweck AV et al. Determinants of bone microarchitecture and mechanical properties in obese men. J Clin Endocrinol Metab 2012; 97(11): 4115–4122. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012–2246>.
  22. Bravenboer N, Holzmann P, de Boer H et al. Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 1996; 18(6): 551–557.
  23. Bravenboer N, Holzmann PJ, ter Maaten JC et al. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res 2005; 20(10): 1778–1784. Dostupné z DOI: <http://dx.doi.org/10.1359/JBMR.050613>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology Osteology
Effect of vitamin K on musculoskeletal health in postmenopausal women
Sarcopenia: definition and diagnosing of a new disease
Importance of bone densitometry in cardiovascular risk prediction
Variability of osteogenesis imperfecta manifestations depending on gender: case report
Effects of vitamin D3, magnesium and vitamin C on bone-associated miRNAs expression in adipose-derived mesenchymal stem cells
Article was published in

Clinical Osteology

Issue 1
2019 Issue 1
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#